Oct 2026· ACS Applied Nano Materials· Vol 9, pp. 20554-20566· 0 citations· 38 references
TL;DR
The as-constructed RG@CSG enables a PA imaging-guided X-ray deposition-cell-cycle arrest-ferroptosis amplification cascade network, achieving a “triple-enhanced” RT sensitization strategy for effective TNBC therapy.
Abstract
Radiotherapy (RT) is crucial in the treatment of triple-negative breast cancer (TNBC). However, insufficient deposition of X-ray energy and peripheral tissue destruction usually caused RT failure. To circumvent this problem, herein, a “three-pronged strategy” nano-radiosensitizer (by encapsulating small molecules RSL3 and Gingerenone A (Gin A) in hollow Cu9S8 deposited with gold nanoparticles, RG@CSG) to combine with ferroptosis induction, G2/M arrest, and energy deposition is rationally designed. After passive accumulation of radiosensitizers at the tumor site, Au nanoparticles (Au NPs) grown on the surface can increase the deposition of X-ray energy to amplify the radiation-induced damage. Subsequently, upon X-ray irradiation, RG@CSG disintegrates to release RSL3 and Gin A. Gin A induces cell cycle arrest in the G2/M phase of tumor cells, which compromises DNA damage repair capacity and enhances tumor sensitivity to irradiation. RSL3 inactivates the GPX4-dependent ferroptosis defense system to eliminate residual tumor cells radioresistance. Furthermore, Au NPs can monitor the therapeutic response via activatable photoacoustic (PA) imaging in the NIR-II region (920 nm). Overall, the as-constructed RG@CSG enables a PA imaging-guided X-ray deposition-cell-cycle arrest-ferroptosis amplification cascade network, achieving a “triple-enhanced” RT sensitization strategy for effective TNBC therapy.
Effective treatment for malignant tumors continues to represent an urgent unmet clinical need. Triple-negative breast cancer (TNBC) constitutes a therapeutic challenge on account of its aggressive nature and limited response to conventional therapies. Radiotherapy serves as a cornerstone for cervical cancer treatment....
Nan Yang, Tu-Sheng Wu, Ying Wang et al.· Biomaterials Science· 0 citations
Purpose To overcome dose-limiting toxicity and paclitaxel (PTX) resistance in triple-negative breast cancer (TNBC) therapy, as well as the asynchronous in vivo biodistribution of PTX and psoralen (PSO) combination regimens, we developed a highly biocompatible, magnetically targeted nano-co-delivery system. Methods Pacl...
Man-Ling Du, Feng-Jie Liu, Pan-Pan Wang et al.· International Journal of Nan...· 0 citations
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with radioresistance and limited treatment options. Titanium dioxide nanoparticles (TiO2-NPs) have attracted attention as potential radiosensitizers because they can enhance radiation-induced oxidative stress. This study evaluated th...
Combined chemo-radionuclide therapy offers a promising strategy to improve cancer treatment by integrating various therapeutic mechanisms within a single drug delivery system (DDS). Metal-organic frameworks (MOFs), owing to their porous structure and tunable physicochemical properties, provide a unique platform for dev...
D. Akhmetova, V. Rusakova, D. Matveev et al.· ACS Applied Bio Materials· 0 citations
Background Gastric cancer (GC) remains a major global malignancy with limited therapeutic options for advanced disease. Ubiquitin-specific peptidase 8 (USP8) is a deubiquitinating enzyme involved in tumor progression and immune regulation, but its therapeutic potential in GC remains incompletely explored. Methods Publi...
Qing Zheng, Huai-Ming Wang, Jie-Hao Huang· International Journal of Nan...· 0 citations
Triple-negative breast cancer (TNBC) remains a challenge to oncologists all over the world due to its receptor-negative phenotype, remarkable molecular heterogeneity, and high resistance to traditional systemic therapies. The current study reports the rational design, systematic optimization and in-depth biological tes...
Shraddha Ram, Akshay M. Baheti· International Journal of Dru...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.